The I-SPY2 trial (ClinicalTrials.gov identifier: NCT01042379) was the first randomized trial to examine the efficacy of IO therapy in patients with high-risk HR+HER2– breast cancers, followed by KEYNOTE-7562 and CheckMate-7FL.3 This evidence concerns the gene ERBB2 and breast carcinoma.